Should I buy or sell Immatics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMTX shares. View IMTX analyst ratings or view top-rated stocks .

How have IMTX shares performed in 2024?

Immatics' stock was trading at $10.53 at the start of the year. Since then, IMTX shares have decreased by 2.1% and is now trading at $10.31. View the best growth stocks for 2024 here .

Are investors shorting Immatics?

Immatics saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,910,000 shares, an increase of 6.2% from the March 15th total of 8,390,000 shares. Based on an average daily volume of 526,500 shares, the short-interest ratio is presently 16.9 days. View Immatics' Short Interest .

When is Immatics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our IMTX earnings forecast .

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.09. The company earned $17.14 million during the quarter, compared to the consensus estimate of $11.78 million. Immatics had a negative trailing twelve-month return on equity of 43.58% and a negative net margin of 179.67%.

What ETFs hold Immatics' stock?

ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD) , Chimerix (CMRX) , Datadog (DDOG) , Forte Biosciences (FBRX) , Great Panther Mining (GPL) , Idera Pharmaceuticals (IDRA) and Immunic (IMUX) .

How do I buy shares of Immatics?

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMTX

Immatics (IMTX) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free IMTX Stock Alerts

$10.37

-0.03 (-0.29%)

(As of 12:50 PM ET)

Compare

Today's Range: $10.25
▼
$10.39
50-Day Range: $10.40
▼
$12.94
52-Week Range: $6.31
▼
$13.16

Volume: 67,989 shs
Average Volume: 497,241 shs
Market Capitalization: $877.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Immatics alerts:

Immatics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
10.52% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.44) to ($1.50) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.02 out of 5 stars

Medical Sector

929th out of 930 stocks

Biological Products, Except Diagnostic Industry

155th out of 155 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Immatics.

0.0

Short Interest

Percentage of Shares Shorted
10.52% of the outstanding shares of Immatics have been sold short.
Short Interest Ratio / Days to Cover
Immatics has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Immatics has recently increased by 6.20%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Immatics does not currently pay a dividend.
Dividend Growth
Immatics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMTX.

2.5

News and Social Media Coverage

News Sentiment
Immatics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Immatics this week, compared to 1 article on an average week.
Search Interest
2 people have searched for IMTX on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immatics insiders have not sold or bought any company stock.
Percentage Held by Institutions
64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immatics are expected to decrease in the coming year, from ($1.44) to ($1.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immatics is -7.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immatics is -7.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immatics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Immatics Stock (NASDAQ:IMTX)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial; and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

IMTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMTX Stock News Headlines

April 16, 2024 | americanbankingnews.com

Immatics (NASDAQ:IMTX) Short Interest Update

March 29, 2024 | markets.businessinsider.com

Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 21, 2024 | investorplace.com

IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023

March 21, 2024 | globenewswire.com

Immatics Announces Full Year 2023 Financial Results and Corporate Update

March 15, 2024 | finance.yahoo.com

With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns

March 10, 2024 | seekingalpha.com

Cantor sees strong year ahead for oncology M&A

March 10, 2024 | msn.com

Cantor Fitzgerald sees strong year ahead for oncology M&A

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic Partnerships

February 28, 2024 | seekingalpha.com

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

February 6, 2024 | uk.yahoo.com

Bolton TV star to 'go back to Fernandos one last time' as he spreads the love

February 3, 2024 | finance.yahoo.com

Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year

February 3, 2024 | seekingalpha.com

Immatics: Pioneering TCR Therapies In The Fight Against Cancer

January 17, 2024 | msn.com

Immatics commences public offering of shares

January 17, 2024 | finance.yahoo.com

Immatics Announces Pricing of $175 Million Public Offering

January 17, 2024 | finance.yahoo.com

Immatics Announces Proposed Public Offering

November 20, 2023 | markets.businessinsider.com

Positive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh’s Recommendation

November 16, 2023 | markets.businessinsider.com

Immatics: Strong Buy Rating Supported by Promising Clinical Results and Upcoming Catalysts

November 14, 2023 | markets.businessinsider.com

Immatics Announces Third Quarter 2023 Financial Results and Business Update

November 8, 2023 | finanznachrichten.de

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

November 6, 2023 | finance.yahoo.com

Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?

November 3, 2023 | nasdaq.com

Cantor Fitzgerald Initiates Coverage of Immatics N.V (IMTX) with Overweight Recommendation

October 24, 2023 | finance.yahoo.com

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

October 12, 2023 | msn.com

Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)

October 9, 2023 | seekingalpha.com

Analyzing Immatics' Multi-Faceted Investment Case

September 21, 2023 | finance.yahoo.com

IMTX Oct 2023 10.000 put

See More Headlines

Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:IMTX
CUSIP: N/A
CIK: 1809196
Web: www.immatics.com
Phone: 4.97072E+12
Fax: N/A
Employees: 432
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-104,980,000.00
Net Margins: -179.67%
Pretax Margin: -179.63%
Return on Equity: -43.58%
Return on Assets: -22.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.87
Quick Ratio: 2.87

Sales & Book Value

Annual Sales: $58.44 million
Price / Sales: 15.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.88 per share
Price / Book: 3.61

Miscellaneous

Outstanding Shares: 84,660,000
Free Float: N/A
Market Cap: $880.46 million
Optionable: Optionable
Beta: 0.67

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Harpreet Singh Ph.D. (Age 49)
CEO, MD, Member of Management Board & Executive Director
Comp: $897.96k
Dr. Toni Weinschenk Ph.D. (Age 50)
Co-Founder & Chief Innovation Officer
Mr. Arnd Christ MBA (Age 58)
Chief Financial Officer
Mr. Steffen Walter Ph.D. (Age 47)
Chief Operations Officer
Mr. Edward A. Sturchio J.D. (Age 48)
General Counsel & Secretary
Dr. Carsten Reinhardt M.D. (Age 57)
Ph.D., Chief Development Officer
Mr. Cedrik M. Britten M.D. (Age 48)
Chief Medical Officer
Mr. Jordan Silverstein (Age 44)
Head of Strategy
Dr. Hans-Georg Rammensee Ph.D.
Co-Founder & Member of the Scientific Advisory Board
Mr. Ephraim Hofsäß M.Sc.
Vice President of SEC Reporting & Accounting

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IMTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immatics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings or view top-rated stocks.
How have IMTX shares performed in 2024?: Immatics' stock was trading at $10.53 at the start of the year. Since then, IMTX shares have decreased by 2.1% and is now trading at $10.31.
View the best growth stocks for 2024 here.
Are investors shorting Immatics?: Immatics saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,910,000 shares, an increase of 6.2% from the March 15th total of 8,390,000 shares. Based on an average daily volume of 526,500 shares, the short-interest ratio is presently 16.9 days.
View Immatics' Short Interest.
When is Immatics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our IMTX earnings forecast.

How were Immatics' earnings last quarter?: Immatics (NASDAQ:IMTX) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.09. The company earned $17.14 million during the quarter, compared to the consensus estimate of $11.78 million. Immatics had a negative trailing twelve-month return on equity of 43.58% and a negative net margin of 179.67%.
What ETFs hold Immatics' stock?: ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of Immatics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).
How do I buy shares of Immatics?: Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immatics (IMTX) Stock Price, News & Analysis

Immatics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immatics Stock (NASDAQ:IMTX)

IMTX Stock Price History

IMTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

IMTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™